2. Share Prices
3. Avacta Group Share Price
4. Avacta Group Share News
5. UK Shareholder Meetings Calendar - Next 7 Days

Avacta Group Share News (AVCT)

• AVCT Share
  Price
• AVCT Share
  News0
• AVCT Share
  Chat24
• AVCT Share
  Trades207
• AVCT
  Live RNS0
• AVCT Share
  Charts
• AVCT Level 2
  Console
• AVCT Live
  Share Price
• AVCT Broker
  Ratings0
• AVCT Directors
  Deals0
• AVCT Financial
  Diary
• AVCT
  Fundamentals
• AVCT Short
  Positions1
• AVCT
  Media0

• Buy AVCT Shares
• Add AVCT to Watchlist
• Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 42.75

Bid: 42.00

Ask: 43.50

Change: -2.60 (-6.05%)

Spread: 1.50 (3.571%)

Open: 42.75

High: 40.40

Low: 40.40

Prev. Close: 43.00

Last checked at -

• AVCT News
• AVCT Professional News

UK Shareholder Meetings Calendar - Next 7 Days

Mon, 15th Jun 2020 15:52

Tuesday 16 June

Marshall Motor

Clearstar

Epwin Group

Coca-Cola HBC

Science Group

Altus Strategies

Arbuthnot Banking

Evraz

Andrews Sykes Group

FDM Group

Wednesday 17 June

Amigo Holdings (re board removal)

RTC Group

Wentworth Resources

STM Group

Salt Lake Potash

Domino's Pizza Group

Pelatro

UK Oil & Gas

G4S

Thursday 18 June

Ted Baker (re share placing)

IP Group

Horizon Discovery

Ten Entertainment

Shield Therapeutics

Tremor International

Jadestone Energy

Vietnam Enterprise

Intelligent Ultrasound Group

Block Energy

RBG Holdings

Impact Healthcare

Michelmersh

Immupharma

Friday 19 June

boohoo

Power Metal Resources

Costain Group

Learning Technologies Group

John Wood Group

Trinty Exploration

AA

Monday 22 June

Ethernity Networks

SAGA

Wincanton

Avacta

President Energy

Copyright 2020 Alliance News Limited. All Rights Reserved.

28 Jan 2020 11:57

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Avacta Demonstrates Initial Proof Of Concept For Cancer Drug TMAC

Read more

23 Jan 2020 12:44

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Affimer Unit Performance Helps Avacta Revenue Beat Market Forecasts

Read more

23 Jan 2020 10:28

Avacta doubles revenues thanks to LG Chem milestone payment

(Sharecast News) - Biotherapeutics development outfit Avacta doubled revenues in the 17-month period ended 31 December 2019 as it was boosted by an initial milestone payment from LG Chem.

Read more

21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more

8 Jan 2020 15:27

Avacta Group enters joint venture with South Korea's Daewoong

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.

Read more

8 Jan 2020 10:40

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma

Read more

13 Nov 2019 13:51

Avacta Expands Contract With LG Chem After First Programme Completes

Avacta Expands Contract With LG Chem After First Programme Completes

Read more

13 Nov 2019 11:50

Avacta Group reports solid progress in partnership with LG Chem

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.

Read more

4 Nov 2019 18:15

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Avacta Non-Executive Sam Williams Steps Down After General Meeting

Read more

18 Oct 2019 13:20

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Read more

10 Oct 2019 11:24

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Read more

10 Oct 2019 08:39

Avacta inks collaboration deal with ADC Therapeutics

(Sharecast News) - Biotechnology company Avacta Group has entered a collaboration and option agreement with ADC Therapeutics, which it described as a Switzerland-based clinical-stage oncology-focused biotechnology company pioneering the development of "highly potent and targeted" antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours.

Read more

20 Jun 2019 10:28

Avacta partners with Selexis ahead of first-in-human trials

(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.

Read more

10 Jun 2019 10:51

Avacta Selects Candidate For First Human Trials Of Affimer Platform

LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a

Read more

3 Jun 2019 10:20

Avacta To Submit Application For TMAC Linker Testing In Tumours Study

LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a

Read more